Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma
Abstract
:Simple Summary
Abstract
1. Introduction
2. Patients and Methods
2.1. Study Design and Data Collection
2.2. Patients
2.3. Pre-Treatment Assessment
2.4. Treatment
2.5. Follow-Up
2.6. NTCP Calculations
2.7. Statistical Analysis
3. Results
3.1. Outcomes
3.2. Toxicities
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
CDLR | Cutoff dose logistic regression model |
CT | Computed tomography |
CTV | Clinical target volume |
EBV | Epstein-Barr virus |
ECE | Extracapsular extension |
GTV | Gross tumor volume |
Gy | Gray |
IMRT | Intensity-modulated radiotherapy |
LN | lymph node |
LRC | Locoregional control |
MRI | Magnetic resonance imaging |
NPC | Nasopharyngeal carcinoma |
NTCP | Normal tissue complication rate |
OAR | Organs at risk |
OS | Overall survival |
PET | Positron emission tomography |
PFS | Progression free survival |
PTV | Planning target volume |
RCT | Radiochemotherapy |
RT | Radiotherapy |
VMAT | Volumetric intensity modulated arc therapy |
References
- Chang, E.T.; Adami, H.O. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma. Cancer Epidemiol. Prev. Biomark. 2006, 15, 1765–1777. [Google Scholar] [CrossRef] [Green Version]
- Wei, W.I.; Sham, J.S. Nasopharyngeal carcinoma. Lancet 2005, 365, 2041–2054. [Google Scholar] [CrossRef]
- Lee, N.; Xia, P.; Quivey, J.M.; Sultanem, K.; Poon, I.; Akazawa, C.; Akazawa, P.; Weinberg, V.; Fu, K.K. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int. J. Radiat. Oncol. 2002, 53, 12–22. [Google Scholar] [CrossRef]
- Lee, A.W.M.; Lin, J.C.; Ng, W.T. Current Management of Nasopharyngeal Cancer. Semin. Radiat. Oncol. 2012, 22, 233–244. [Google Scholar] [CrossRef]
- Wei, Y.; Zhou, T.; Zhu, J.; Zhang, Y.; Sun, M.; Ding, X.; Wang, D.; Li, H.; Li, B. Long-Term Outcome of Sensorineural Hearing Loss in Nasopharyngeal Carcinoma Patients: Comparison Between Treatment with Radiotherapy Alone and Chemoradiotherapy. Cell Biochem. Biophys. 2014, 69, 433–437. [Google Scholar] [CrossRef]
- Santos, N.A.G.D.; Ferreira, R.S.; Santos, A.C.D. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem. Toxicol. 2020, 136, 111079. [Google Scholar] [CrossRef]
- Burman, C.; Kutcher, G.; Emami, B.; Goitein, M. Fitting of normal tissue tolerance data to an analytic function. Int. J. Radiat. Oncol. Biol. Phys. 1991, 21, 123–135. [Google Scholar] [CrossRef]
- Lee, T.F.; Yeh, S.A.; Chao, P.J.; Chang, L.; Chiu, C.L.; Ting, H.M.; Wang, H.Y.; Huang, Y.J. Normal tissue complication probability modeling for cochlea constraints to avoid causing tinnitus after head-and-neck intensity-modulated radiation therapy. Radiat. Oncol. 2015, 10, 194. [Google Scholar] [CrossRef] [Green Version]
- Pan, C.C.; Eisbruch, A.; Lee, J.S.; Snorrason, R.M.; Ten Haken, R.K.; Kileny, P.R. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 1393–1402. [Google Scholar] [CrossRef]
- Lee, A.W.; Ng, W.; Chan, L.; Chan, O.S.; Hung, W.; Chan, C.; Cheng, P.T.; Sze, H.; Lam, T.; Yau, T. The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. Oral Oncol. 2012, 48, 1007–1013. [Google Scholar] [CrossRef]
- Pan, J.J.; Ng, W.T.; Zong, J.F.; Chan, L.L.K.; O’Sullivan, B.; Lin, S.J.; Sze, H.C.K.; Chen, Y.B.; Choi, H.C.W.; Guo, Q.J.; et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 2016, 122, 546–558. [Google Scholar] [CrossRef] [Green Version]
- Sun, Y.; Yu, X.L.; Luo, W.; Lee, A.W.M.; Wee, J.T.S.; Lee, N.; Zhou, G.Q.; Tang, L.L.; Tao, C.J.; Guo, R.; et al. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Radiother. Oncol. 2014, 110, 390–397. [Google Scholar] [CrossRef] [Green Version]
- Lee, A.W.; Ng, W.T.; Pan, J.J.; Poh, S.S.; Ahn, Y.C.; AlHussain, H.; Corry, J.; Grau, C.; Grégoire, V.; Harrington, K.J.; et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiother. Oncol. 2018, 126, 25–36. [Google Scholar] [CrossRef]
- Grégoire, V.; Ang, K.; Budach, W.; Grau, C.; Hamoir, M.; Langendijk, J.A.; Lee, A.; Le, Q.T.; Maingon, P.; Nutting, C.; et al. Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother. Oncol. 2014, 110, 172–181. [Google Scholar] [CrossRef]
- National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available online: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (accessed on 30 March 2022).
- Troeller, A. Normal Tissue Complication Probability Modeling: Influence of Technique, Fractionation, and Dose Calculation Algorithm. Ph.D. Thesis, Ludwig-Maximilians-Universität München, München, Germany, 2016. [Google Scholar]
- Kaplan, E.L.; Meier, P. Nonparametric Estimation from Incomplete Observations. J. Am. Stat. Assoc. 1958, 53, 457–481. [Google Scholar] [CrossRef]
- Chen, W.C.; Jackson, A.; Budnick, A.S.; Pfister, D.G.; Kraus, D.H.; Hunt, M.A.; Stambuk, H.; Levegrun, S.; Wolden, S.L. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006, 106, 820–829. [Google Scholar] [CrossRef]
- Bhandare, N.; Antonelli, P.J.; Morris, C.G.; Malayapa, R.S.; Mendenhall, W.M. Ototoxicity after radiotherapy for head and neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 469–479. [Google Scholar] [CrossRef]
- Espenel, S.; Garcia, M.A.; Guy, J.B.; Vallard, A.; Ben Mrad, M.; Langrand-Escure, J.; El Meddeb Hamrouni, A.; Trone, J.C.; Xia, Y.; Rancoule, C.; et al. Ototoxicité radio-induite et chimio-induite dans les cancers ORL: De la prévention primaire à la prévention tertiaire. Cancer 2017, 21, 77–83. [Google Scholar] [CrossRef]
- Chan, S.H.; Ng, W.T.; Kam, K.L.; Lee, M.C.H.; Choi, C.W.; Yau, T.K.; Lee, A.W.M.; Chow, S.K. Sensorineural Hearing Loss After Treatment of Nasopharyngeal Carcinoma: A Longitudinal Analysis. Int. J. Radiat. Oncol. 2009, 73, 1335–1342. [Google Scholar] [CrossRef]
- Grau, C.; Møller, K.; Overgaard, M.; Overgaard, J.; Elbrønd, O. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1991, 21, 723–728. [Google Scholar] [CrossRef]
- Young, Y.H. Irradiated ears in nasopharyngeal carcinoma survivors: A review. Laryngoscope 2019, 129, 637–642. [Google Scholar] [CrossRef]
- Bhandare, N.; Jackson, A.; Eisbruch, A.; Pan, C.C.; Flickinger, J.C.; Antonelli, P.; Mendenhall, W.M. Radiation Therapy and Hearing Loss. Int. J. Radiat. Oncol. 2010, 76, S50–S57. [Google Scholar] [CrossRef] [Green Version]
- Hoeller, U.; Borgmann, K.; Oertel, M.; Haverkamp, U.; Budach, V.; Eich, H.T. Late Sequelae of Radiotherapy—The Effect of Technical and Conceptual Innovations in Radiation Oncology. Dtsch. Arztebl. Int. 2021, 118, 205–211. [Google Scholar] [CrossRef]
- Kam, M.K.; Leung, S.F.; Zee, B.; Chau, R.M.; Suen, J.J.; Mo, F.; Lai, M.; Ho, R.; Cheung, K.Y.; Yu, B.K.; et al. Prospective Randomized Study of Intensity-Modulated Radiotherapy on Salivary Gland Function in Early-Stage Nasopharyngeal Carcinoma Patients. J. Clin. Oncol. 2007, 25, 4873–4879, Publisher: Wolters Kluwer. [Google Scholar] [CrossRef]
- Pow, E.H.N.; Kwong, D.L.W.; McMillan, A.S.; Wong, M.C.M.; Sham, J.S.T.; Leung, L.H.T.; Leung, W.K. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. Int. J. Radiat. Oncol. 2006, 66, 981–991. [Google Scholar] [CrossRef]
- Fang, F.M.; Tsai, W.L.; Lee, T.F.; Liao, K.C.; Chen, H.C.; Hsu, H.C. Multivariate analysis of quality of life outcome for nasopharyngeal carcinoma patients after treatment. Radiother. Oncol. 2010, 97, 263–269. [Google Scholar] [CrossRef]
- Guimas, V.; Thariat, J.; Graff-Cailleau, P.; Boisselier, P.; Pointreau, Y.; Pommier, P.; Montbarbon, X.; Laude, C.; Racadot, S. Radiothérapie conformationnelle avec modulation d’intensité des cancers des voies aérodigestives supérieures, dose de tolérance des tissus sains: Appareil cochléovestibulaire et tronc cérébral. Cancer 2016, 20, 475–483. [Google Scholar] [CrossRef]
- Liu, F.; Luo, T.; Jin, T.; Zhang, J.; Xiang, Z.; Yan, R.; Xie, L.; Wu, X.; Zhang, H.; Wang, F.; et al. Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: A retrospective paired study. BMC Cancer 2019, 19, 554. [Google Scholar] [CrossRef] [Green Version]
- Lamaj, E.; Vu, E.; van Timmeren, J.E.; Leonardi, C.; Marc, L.; Pytko, I.; Guckenberger, M.; Balermpas, P. Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma. Radiat. Oncol. 2021, 16, 64. [Google Scholar] [CrossRef]
- Braun, L.H.; Braun, K.; Frey, B.; Wolpert, S.M.; Löwenheim, H.; Zips, D.; Welz, S. Unilateral cochlea sparing in locoregionally advanced head and neck cancer: A planning study. Strahlentherapie Onkologie 2018, 194, 1124–1131. [Google Scholar] [CrossRef]
Age Range 19–87 Years / Mean Age 57 Years / () | ||
---|---|---|
Characteristics | Affected Patients | Percentage % |
Sex | ||
Female | 18 | 39.1 |
Male | 28 | 60.9 |
Primary location | ||
Nasopharynx | 41 | 89.1 |
Naso-/Oropharynx | 5 | 10.9 |
Histology | ||
Squamous cell carcinoma | 18 | 39.1 |
Anaplastic carcinoma | 10 | 21.7 |
Adenocarcinoma | 4 | 8.7 |
Adenoid cystic carcinoma | 3 | 6.5 |
Neuroendocrine carcinoma | 2 | 4.3 |
Transitional cell carcinoma | 2 | 4.3 |
other | 2 | 4.3 |
unknown | 5 | 10.9 |
Grading | ||
Grade 1 | 1 | 2.2 |
Grade 2 | 7 | 15.2 |
Grade 3 | 15 | 32.6 |
Grade 4 | 12 | 26.1 |
unknown | 11 | 23.9 |
TNM-Classification * | ||
T stage 1 | 9 | 19.6 |
2 | 11 | 23.9 |
3 | 15 | 32.6 |
4 | 10 | 21.7 |
N stage 1 | 9 | 19.6 |
2 | 9 | 19.6 |
3 | 5 | 10.9 |
M stage 0 | 43 | 93.5 |
1 | 2 | 4.3 |
Staging * | ||
Stage 1 | 2 | 4.3 |
Stage 2 | 6 | 13.0 |
Stage 3 | 24 | 52.2 |
Stage 4a | 11 | 23.9 |
Stage 4b | 2 | 4.3 |
Recurrence | ||
none | 22 | 47.8 |
locoregional | 7 | 15.2 |
distant | 4 | 8.7 |
unknown | 13 | 28.3 |
Radiotherapy technique | ||
IMRT | 45 | 97.8 |
3D-CRT | 1 | 2.2 |
Chemotherapy | ||
prior | 1 | 2.2 |
concurrent | 36 | 78.3 |
adjuvant | 12 | 26.1 |
Type |
Occurring Cases |
Cases in % () |
Cases in % () |
---|---|---|---|
Leukopenia | 15 | 32.6 | 40.5 |
Nausea/emesis | 9 | 19.6 | 24.3 |
Dysphagia/ odynophagia | 8 | 17.4 | 21.6 |
Decrease of performance status | 4 | 8.7 | 10.8 |
Inner ear side effects | 4 | 8.7 | 10.8 |
Mucositis | 3 | 6.5 | 8.1 |
Oral candidiasis | 2 | 4.3 | 5.4 |
Fatigue | 2 | 4.3 | 5.4 |
Polyneuropathy | 2 | 4.3 | 5.4 |
Type | Occurring Cases | Grade 1 | Grade 2 | Grade 3 | Unknown Grade |
---|---|---|---|---|---|
Dermatitis | 30 (65.2%) | 7 (15.2%) | 12 (26.1%) | 7 (15.2%) | 4 (8.7%) |
Mucositis | 24 (52.2%) | 6 (13.0%) | 3 (6.5%) | 6 (13.0%) | 9 (19.6%) |
Type | Occurring Cases | Grade 1 | Grade 2 | Grade 3 | Unknown Grade |
---|---|---|---|---|---|
Xerostomia | 29 (63.0%) | - | - | - | - |
Dysgeusia | 20 (43.5%) | 17 (37.0%) | 3 (6.5%) | - | - |
Dysphagia | 16 (34.8%) | 6 (13.3%) | 4 (8.7%) | 1 (2.2%) | 5 (10.9%) |
Hearing impairment | 7 (15.2%) | 2 (4.3%) | 2 (4.3%) | 3 (6.5%) | - |
Tinnitus | 4 (8.7%) | 4 (8.7%) | - | - | - |
Fatigue | 8 (17.4%) | - | - | - | - |
Dysphonia | 6 (13.0%) | - | - | - | - |
Type | m | ||
---|---|---|---|
mean | |||
max |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Peuker, L.; Rolf, D.; Oertel, M.; Peuker, A.; Scobioala, S.; Hering, D.; Rudack, C.; Haverkamp, U.; Eich, H.T. Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma. Cancers 2022, 14, 3422. https://doi.org/10.3390/cancers14143422
Peuker L, Rolf D, Oertel M, Peuker A, Scobioala S, Hering D, Rudack C, Haverkamp U, Eich HT. Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma. Cancers. 2022; 14(14):3422. https://doi.org/10.3390/cancers14143422
Chicago/Turabian StylePeuker, Leonie, Daniel Rolf, Michael Oertel, Alexander Peuker, Sergiu Scobioala, Dominik Hering, Claudia Rudack, Uwe Haverkamp, and Hans Theodor Eich. 2022. "Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma" Cancers 14, no. 14: 3422. https://doi.org/10.3390/cancers14143422